Affordable Access

Bacterial vaginosis: treatment with topical intravaginal clindamycin phosphate.

Authors
  • Livengood, C H 3rd
  • Thomason, J L
  • Hill, G B
Type
Published Article
Journal
Obstetrics and Gynecology
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Jul 01, 1990
Volume
76
Issue
1
Pages
118–123
Identifiers
PMID: 2193261
Source
Medline
License
Unknown

Abstract

We tested topical intravaginal clindamycin phosphate at concentrations of 0.1, 1.0, and 2.0% in the treatment of 62 women with symptomatic bacterial vaginosis in a prospective, randomized, double-blind, placebo-controlled trial, and offered open-label treatment with 1.0% clindamycin to patients with persistent disease after blinded treatment. Blinded intravaginal clindamycin phosphate treatment cured bacterial vaginosis in 93.5% (43 of 46) of patients 4-7 days after therapy, compared with 25.0% (four of 16) of patients receiving placebo (P less than .001). One month later, 89.7% (35 of 39) of those who initially responded to clindamycin treatment showed persistent cure. There were no significant side effects.

Report this publication

Statistics

Seen <100 times